Skip to Content

Smith & Nephew PLC

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
GBX 4,625.00RkfrgbsQkwpmtrw

Smith & Nephew Seeks to Expand Presence in ASCs; Modestly Lowering Our Fair Value Estimate

We’ve modestly lowered our fair value estimate on Smith & Nephew to $40 per ADR (GBX 1513 local share class), from $43 (GBX 1534), after adjusting our assumptions slightly downward for lower profitability from the orthopedic segment as Smith & Nephew assertively pursues expansion in ambulatory surgical centers, as well as higher input and transportation costs in the near term. In our base case, we continue to assume hips, knees, and sports medicine will return to more normal growth in 2022 as more elective orthopedic, sports medicine, and ENT (Ear, Nose, and Throat) procedures are rescheduled.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of SN. so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center